Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS

Gerwin Huls; Dana A. Chitu; Thomas Pabst; Saskia K. Klein; Georg Stussi; Laimonas Griskevicius; Peter J. M. Valk; Jacqueline Cloos; Arjan A. van de Loosdrecht; Dimitri Breems; Danielle van Lammeren-Venema; Isabelle van Zeventer; Rinske Boersma; Mojca Jongen-Lavrencic; Martin Fehr; Mels Hoogendoorn; Markus G. Manz; Maaike Sohne; Rien van Marwijk Kooy; Dries Deeren; Marjolein W. M. van der Poel; Marie Cecile Legdeur; Lidwine Tick; Yves Chalandon; Emanuele Ammatuna; Sabine Blum; Bob Lowenberg; Gert J. Ossenkoppele; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON); Swiss Group for Clinical Cancer Research (SAKK)

doi:10.1182/bloodadvances.2020002846

Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS

Gerwin Huls^*, Dana A. Chitu, Thomas Pabst, Saskia K. Klein, Georg Stussi, Laimonas Griskevicius, Peter J. M. Valk, Jacqueline Cloos, Arjan A. van de Loosdrecht, Dimitri Breems, Danielle van Lammeren-Venema, Isabelle van Zeventer, Rinske Boersma, Mojca Jongen-Lavrencic, Martin Fehr, Mels Hoogendoorn, Markus G. Manz, Maaike Sohne, Rien van Marwijk Kooy, Dries DeerenMarjolein W. M. van der Poel, Marie Cecile Legdeur, Lidwine Tick, Yves Chalandon, Emanuele Ammatuna, Sabine Blum, Bob Lowenberg, Gert J. Ossenkoppele, Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), Swiss Group for Clinical Cancer Research (SAKK)

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	4267-4277
Number of pages	11
Journal	Blood advances
Volume	4
Issue number	18
DOIs	https://doi.org/10.1182/bloodadvances.2020002846
Publication status	Published - 22 Sep 2020

Keywords

ACUTE MYELOID-LEUKEMIA
MINIMAL RESIDUAL DISEASE
HYPOMETHYLATING AGENT THERAPY
CONVENTIONAL CARE REGIMENS
MYELODYSPLASTIC SYNDROME
AZACITIDINE THERAPY
TREATMENT RESPONSE
CLINICAL-RESPONSE
SURVIVAL
TRIAL

Access to Document

10.1182/bloodadvances.2020002846

Cite this

Huls, G., Chitu, D. A., Pabst, T., Klein, S. K., Stussi, G., Griskevicius, L., Valk, P. J. M., Cloos, J., van de Loosdrecht, A. A., Breems, D., van Lammeren-Venema, D., van Zeventer, I., Boersma, R., Jongen-Lavrencic, M., Fehr, M., Hoogendoorn, M., Manz, M. G., Sohne, M., Kooy, R. V. M., ... Swiss Group for Clinical Cancer Research (SAKK) (2020). Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS. Blood advances, 4(18), 4267-4277. https://doi.org/10.1182/bloodadvances.2020002846

Huls, Gerwin ; Chitu, Dana A. ; Pabst, Thomas ; Klein, Saskia K. ; Stussi, Georg ; Griskevicius, Laimonas ; Valk, Peter J. M. ; Cloos, Jacqueline ; van de Loosdrecht, Arjan A. ; Breems, Dimitri ; van Lammeren-Venema, Danielle ; van Zeventer, Isabelle ; Boersma, Rinske ; Jongen-Lavrencic, Mojca ; Fehr, Martin ; Hoogendoorn, Mels ; Manz, Markus G. ; Sohne, Maaike ; Kooy, Rien van Marwijk ; Deeren, Dries ; van der Poel, Marjolein W. M. ; Legdeur, Marie Cecile ; Tick, Lidwine ; Chalandon, Yves ; Ammatuna, Emanuele ; Blum, Sabine ; Lowenberg, Bob ; Ossenkoppele, Gert J. ; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) ; Swiss Group for Clinical Cancer Research (SAKK). / Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS. In: Blood advances. 2020 ; Vol. 4, No. 18. pp. 4267-4277.

@article{ab2d8f98eeeb42e3a120a30305be17c3,

title = "Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS",

keywords = "ACUTE MYELOID-LEUKEMIA, MINIMAL RESIDUAL DISEASE, HYPOMETHYLATING AGENT THERAPY, CONVENTIONAL CARE REGIMENS, MYELODYSPLASTIC SYNDROME, AZACITIDINE THERAPY, TREATMENT RESPONSE, CLINICAL-RESPONSE, SURVIVAL, TRIAL",

author = "Gerwin Huls and Chitu, {Dana A.} and Thomas Pabst and Klein, {Saskia K.} and Georg Stussi and Laimonas Griskevicius and Valk, {Peter J. M.} and Jacqueline Cloos and {van de Loosdrecht}, {Arjan A.} and Dimitri Breems and {van Lammeren-Venema}, Danielle and {van Zeventer}, Isabelle and Rinske Boersma and Mojca Jongen-Lavrencic and Martin Fehr and Mels Hoogendoorn and Manz, {Markus G.} and Maaike Sohne and Kooy, {Rien van Marwijk} and Dries Deeren and {van der Poel}, {Marjolein W. M.} and Legdeur, {Marie Cecile} and Lidwine Tick and Yves Chalandon and Emanuele Ammatuna and Sabine Blum and Bob Lowenberg and Ossenkoppele, {Gert J.} and {Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON)} and {Swiss Group for Clinical Cancer Research (SAKK)}",

year = "2020",

month = sep,

day = "22",

doi = "10.1182/bloodadvances.2020002846",

language = "English",

volume = "4",

pages = "4267--4277",

journal = "Blood advances",

issn = "2473-9529",

publisher = "The American Society of Hematology",

number = "18",

}

Huls, G, Chitu, DA, Pabst, T, Klein, SK, Stussi, G, Griskevicius, L, Valk, PJM, Cloos, J, van de Loosdrecht, AA, Breems, D, van Lammeren-Venema, D, van Zeventer, I, Boersma, R, Jongen-Lavrencic, M, Fehr, M, Hoogendoorn, M, Manz, MG, Sohne, M, Kooy, RVM, Deeren, D, van der Poel, MWM, Legdeur, MC, Tick, L, Chalandon, Y, Ammatuna, E, Blum, S, Lowenberg, B, Ossenkoppele, GJ, Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) & Swiss Group for Clinical Cancer Research (SAKK) 2020, 'Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS', Blood advances, vol. 4, no. 18, pp. 4267-4277. https://doi.org/10.1182/bloodadvances.2020002846

Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS. / Huls, Gerwin; Chitu, Dana A.; Pabst, Thomas; Klein, Saskia K.; Stussi, Georg; Griskevicius, Laimonas; Valk, Peter J. M.; Cloos, Jacqueline; van de Loosdrecht, Arjan A.; Breems, Dimitri; van Lammeren-Venema, Danielle; van Zeventer, Isabelle; Boersma, Rinske; Jongen-Lavrencic, Mojca; Fehr, Martin; Hoogendoorn, Mels; Manz, Markus G.; Sohne, Maaike; Kooy, Rien van Marwijk; Deeren, Dries; van der Poel, Marjolein W. M.; Legdeur, Marie Cecile; Tick, Lidwine; Chalandon, Yves; Ammatuna, Emanuele; Blum, Sabine; Lowenberg, Bob; Ossenkoppele, Gert J.; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON); Swiss Group for Clinical Cancer Research (SAKK).

In: Blood advances, Vol. 4, No. 18, 22.09.2020, p. 4267-4277.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS

AU - Huls, Gerwin

AU - Chitu, Dana A.

AU - Pabst, Thomas

AU - Klein, Saskia K.

AU - Stussi, Georg

AU - Griskevicius, Laimonas

AU - Valk, Peter J. M.

AU - Cloos, Jacqueline

AU - van de Loosdrecht, Arjan A.

AU - Breems, Dimitri

AU - van Lammeren-Venema, Danielle

AU - van Zeventer, Isabelle

AU - Boersma, Rinske

AU - Jongen-Lavrencic, Mojca

AU - Fehr, Martin

AU - Hoogendoorn, Mels

AU - Manz, Markus G.

AU - Sohne, Maaike

AU - Kooy, Rien van Marwijk

AU - Deeren, Dries

AU - van der Poel, Marjolein W. M.

AU - Legdeur, Marie Cecile

AU - Tick, Lidwine

AU - Chalandon, Yves

AU - Ammatuna, Emanuele

AU - Blum, Sabine

AU - Lowenberg, Bob

AU - Ossenkoppele, Gert J.

AU - Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON)

AU - Swiss Group for Clinical Cancer Research (SAKK)

PY - 2020/9/22

Y1 - 2020/9/22

KW - ACUTE MYELOID-LEUKEMIA

KW - MINIMAL RESIDUAL DISEASE

KW - HYPOMETHYLATING AGENT THERAPY

KW - CONVENTIONAL CARE REGIMENS

KW - MYELODYSPLASTIC SYNDROME

KW - AZACITIDINE THERAPY

KW - TREATMENT RESPONSE

KW - CLINICAL-RESPONSE

KW - SURVIVAL

KW - TRIAL

U2 - 10.1182/bloodadvances.2020002846

DO - 10.1182/bloodadvances.2020002846

M3 - Article

C2 - 32915972

VL - 4

SP - 4267

EP - 4277

JO - Blood advances

JF - Blood advances

SN - 2473-9529

IS - 18

ER -